Estrella Immunopharma Files 8-K with Financials
Ticker: ESLAW · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1844417
Sentiment: neutral
Topics: 8-K, financial-statements, company-update
TL;DR
Estrella Immunopharma dropped an 8-K with financials, check it out.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on July 2, 2024, reporting events that occurred on June 26, 2024. The filing includes financial statements and exhibits, and pertains to "Other Events." The company, formerly known as TradeUP Acquisition Corp. until February 4, 2021, is based in Emeryville, California.
Why It Matters
This 8-K filing provides updated information and exhibits for Estrella Immunopharma, Inc., which is important for investors to stay informed about the company's current status and any material events.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial statements and other events, with no immediate indication of significant financial distress or major corporate changes.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- TradeUP Acquisition Corp. (company) — Former company name
- June 26, 2024 (date) — Earliest event reported date
- July 2, 2024 (date) — Filing date
- 5858 Horton Street, Suite 370 (address) — Company business address
- Emeryville, CA (location) — Company location
FAQ
What is the primary purpose of this 8-K filing for Estrella Immunopharma, Inc.?
The primary purpose is to report "Other Events" and to file "Financial Statements and Exhibits" as of June 26, 2024.
When was Estrella Immunopharma, Inc. formerly known as TradeUP Acquisition Corp.?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp. until February 4, 2021.
What is the company's business address and location?
The company's business address is 5858 Horton Street, Suite 370, Emeryville, CA.
What is the Commission File Number for Estrella Immunopharma, Inc.?
The Commission File Number for Estrella Immunopharma, Inc. is 001-40608.
What is the IRS Employer Identification Number for the company?
The IRS Employer Identification Number for Estrella Immunopharma, Inc. is 86-1314502.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-07-01 19:48:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
Filing Documents
- ea0208757-8k_estrella.htm (8-K) — 31KB
- 0001213900-24-058085.txt ( ) — 246KB
- esla-20240626.xsd (EX-101.SCH) — 4KB
- esla-20240626_def.xml (EX-101.DEF) — 26KB
- esla-20240626_lab.xml (EX-101.LAB) — 36KB
- esla-20240626_pre.xml (EX-101.PRE) — 25KB
- ea0208757-8k_estrella_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On June 26, 2024, Estrella Immunopharma, Inc. (the "Company") filed a Certificate of Ownership and Merger with the Delaware Secretary of State to effect a merger (the "Merger") with its wholly-owned subsidiary, Estrella Biopharma, Inc. ("Estrella"), pursuant to Section 253 of the Delaware General Corporation Law. The Merger was approved by resolutions duly adopted by the unanimous written consent of the Company's board of directors. The Merger became effective at 11:59 PM Eastern Time on June 30, 2024, at which time the separate existence of Estrella ceased, and the Company became the surviving corporation. The Merger was effected to simplify the Company's corporate structure and streamline its financial reporting. As a result of the Merger, the Company assumed all assets, liabilities, and obligations of Estrella. Additionally, there were no changes in the Company's management, board composition, ownership, amended and restated certificate of incorporation, or amended and restated bylaws as a result of the Merger.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Dr. Cheng Liu Title: Chief Executive Officer Date: July 1, 2024 2